By the impact of the epidemic, "special drugs" triggered a wave of pharmaceutical stocks, pharmaceutical stocks can be described as a full-blown, but also attracted the attention of many investors. But pharmaceutical stocks are also mixed, for novice investors to start speculation on the leading stocks or more insurance. That you know pharmaceutical leading stocks which ?
1, Jianfan biological (300529): blood perfusion related products stock, China's blood perfusion field leading enterprises. Revenue and net profit for two consecutive years to maintain more than 32% growth, return on net assets of about 24%, gross profit margin of about 84%, dynamic price-earnings ratio of 46 times, the total market value of 24.3 billion.
2, Myriad Medical (300760): leading medical device stocks. Revenue and net profit continued high growth, return on net assets between 28% and 47%, gross profit margin of 66% or so dynamic price-earnings ratio of 44 times, total market capitalization of 177.1 billion. (Foreign to A-share listing)
3, WuXi AppTec (603259): CRO industry leading stocks. Revenue and net profit continued high growth, return on net assets between 21-29%, gross profit margin of 39% or so, dynamic price-earnings ratio of 59 times, total market value of 92.7 billion. (Foreign to A-share listing)
4, Zhaoyan new drugs (603127): 20% or so, gross profit margin of 53% or so of the pharmaceutical preclinical research services stock, the domestic industry leader in the field of security assessment. Revenue and net profit sustained high growth, return on net assets dynamic price-earnings ratio of 153 times, total market capitalization of 7.3 billion.
5, Aide Bio (300685): tumor precision medicine molecular diagnostics leading stocks. Revenue and net profit for three consecutive years to maintain more than 30% growth, return on net assets of about 20%, gross margin of about 91%, dynamic price-earnings ratio of 59 times, total market capitalization of 7.7 billion.
6, OpusCare (300595): the domestic OK lens leading enterprises. Revenue and net profit for many years to maintain more than 30% growth, return on net assets between 21% and 38%, gross profit margin of 77% or so, dynamic price-earnings ratio of 71 times, total market capitalization of 14.4 billion.
7, Dabo medical (002901): medical high health topic stocks, orthopedic implant class domestic leader. Revenue and net profit for three consecutive years to maintain more than 16% growth, return on net assets of more than 28%, gross profit margin of 82% or so, dynamic price-earnings ratio of 40 times, total market capitalization of 13.4 billion.
8, Jianyou shares (603707): pharmaceutical raw materials, preparations, the domestic injection of the internationalization of the pioneer enterprises. Revenue and net profit for three consecutive years to maintain more than 32% growth, return on net assets of about 19%, gross profit margin of about 47%, dynamic price-earnings ratio of 31 times, total market capitalization of 19 billion.
9, Dazanlin (603233): South China's leading pharmaceutical chain. Revenue and net profit for two consecutive years to maintain double-digit growth, return on net assets of 18-37% of the dynamic price-earnings ratio of 31 times, total market value of 22.8 billion.
10, Kelaiying (002821): domestic COMO leading enterprises. Revenue and net profit continued high growth, return on net assets between 17% and 24%, gross profit margin of 46%, dynamic price-earnings ratio of 53 times, total market capitalization of 19.7 billion.